Cargando…
ALKing the flames of lung cancer immunosensitivity
Immune checkpoint inhibitors (ICIs) are utilised in treating non‐small cell lung cancer (NSCLC) by enhancing the immune response against cancer cells. However, they are not effective against cancers with certain genetic alterations. A recent study by Mota et al. focussed on understanding why ALK+ NS...
Autores principales: | Bayliss, Richard, Sarnowska, Elżbieta, Yeoh, Sharon, Sampson, Josephina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620113/ https://www.ncbi.nlm.nih.gov/pubmed/37795653 http://dx.doi.org/10.1002/1878-0261.13533 |
Ejemplares similares
-
EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
por: Elshatlawy, Mariam, et al.
Publicado: (2023) -
A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
por: Sampson, Josephina, et al.
Publicado: (2022) -
New tools for evaluating protein tyrosine sulfation and carbohydrate sulfation
por: Yeoh, Sharon, et al.
Publicado: (2018) -
Phase‐separated foci of EML4‐ALK facilitate signalling and depend upon an active kinase conformation
por: Sampson, Josephina, et al.
Publicado: (2021) -
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
por: Sabir, Sarah R., et al.
Publicado: (2017)